EXC 001 (currently called PF-06473871)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Reduction in Severity of Skin Scarring
Conditions
Reduction in Severity of Skin Scarring
Trial Timeline
Dec 8, 2011 → Sep 10, 2013
NCT ID
NCT01494922About EXC 001 (currently called PF-06473871)
EXC 001 (currently called PF-06473871) is a phase 2 stage product being developed by Pfizer for Reduction in Severity of Skin Scarring. The current trial status is completed. This product is registered under clinical trial identifier NCT01494922. Target conditions include Reduction in Severity of Skin Scarring.
What happened to similar drugs?
2 of 2 similar drugs in Reduction in Severity of Skin Scarring were approved
Approved (2) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01494922 | Phase 2 | Completed |
Competing Products
4 competing products in Reduction in Severity of Skin Scarring
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Biktarvy 50Mg-200Mg-25Mg Tablet | Gilead Sciences | Approved | 43 |
| PF-06473871 + PF-06473871 | Pfizer | Phase 2 | 35 |
| EXC 001 + EXC 001 + EXC 001 + EXC 001 | Pfizer | Phase 2 | 35 |
| 1% preservative-free lidocaine + Phenylephrine 1.0%/ Ketorolac 0.3% | Omeros Corporation | Approved | 29 |